Atea Pharmaceuticals (AVIR) Revenue (2021)

Atea Pharmaceuticals (AVIR) recorded quarterly Revenue of $192.2 million in Q4 2021, up 485.72% quarter-over-quarter from $32.8 million in Q3 2021.

Atea Pharmaceuticals (AVIR) Revenue (2021) Analysis & Trends

Atea Pharmaceuticals' Revenue history runs 1 years deep, the most recent figure standing at $192.2 million for Q4 2021.

In Q4 2021, Revenue changed N/A year-over-year to $192.2 million; the TTM figure through Dec 2021 stood at $351.4 million (changed N/A YoY), while the FY2021 annual figure was $351.4 million, up 622.49% from the prior year.
Revenue was $192.2 million for Q4 2021 at Atea Pharmaceuticals, up from $32.8 million in the prior quarter.
In the past five years, Revenue ranged from a high of $192.2 million in Q4 2021 to a low of $32.8 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	5.21 Mn
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	306.30 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	2.99 Bn
9	Abivax	95.45 Bn	95.45 Bn	-	-
10	Atea Pharmaceuticals	347.68 Mn	347.68 Mn	-	-

Download Data